Illumina (($ILMN)) has held its Q3 earnings call. Read on for the main highlights of the call. Illumina’s recent earnings call painted a picture ...

Illumina’s revenue was flat for the third quarter as the sequencing giant continues to deal with headwinds from a China sales ...

Discover key Q3 2025 earnings insights for Illumina, including raised outlook, NovaSeq X growth, and margin expansion.

Illumina (ILMN) beats Q3 earnings estimates, raises 2023 profit outlook on strong clinical growth. Read more here.

The United States Tumor Profiling Market is projected to surge from US$ 3.41 billion in 2024 to US$ 7.44 billion by 2033, ...

The Chinese DNA sequencing market is expanding rapidly due to rising demand for precision medicine, technological advancements, and government investments. Key opportunities lie in oncology ...

At ASHG, an early access customer from the London Health Sciences Center Research Institute demonstrated the power of the ...

Copyright: © 2025 The Author(s). Published by Elsevier Ltd. In this statistical modelling study, we analysed sequencing data from four studies of untargeted W-MGS to ...

The Internet has Google. Now biology has MetaGraph. Detailed today in Nature, the search engine can quickly sift through the staggering volumes of biological data housed in public repositories. “It’s ...

Illumina is launching a new informatics and artificial intelligence software business aimed at drug developers, with the goal of digesting large-scale DNA sequencing and multi-omics data. The ...

SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of BioInsight, a new business within Illumina, developed to meet industry demand for deeper biologic ...